Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TET2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2	azacitidine Sensitive: C2 – Inclusion Criteria azacitidine Sensitive : C2
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2	HAG + azacitidine Sensitive: C2 – Inclusion Criteria HAG + azacitidine Sensitive : C2
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Resistant : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3	cytarabine Sensitive: C3 – Early Trials cytarabine Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
TET2 mutation	T Cell Non-Hodgkin Lymphoma	TET2 mutation	T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
TET2 mutation	Peripheral T-cell Lymphoma	TET2 mutation	Peripheral T-cell Lymphoma	CHOP Sensitive: C3 – Early Trials CHOP Sensitive : C3	CHOP Sensitive: C3 – Early Trials CHOP Sensitive : C3
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3	gemtuzumab ozogamicin Resistant: C3 – Early Trials gemtuzumab ozogamicin Resistant : C3
TET2 mutation	Chronic Myelomonocytic Leukemia	TET2 mutation	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D